We have merged with Isoray to become
Click for details

A New Line of Sight Into
Targeted Cancer Therapies
Developing a Novel Class of Targeted
Alpha-Particle Radiopharmaceuticals
A New Line of Sight Into Targeted Cancer Therapies
Developing a Novel Class of Targeted
Alpha-Particle Radiopharmaceuticals
We are an alpha-particle radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents.

Our new, proprietary class of theranostics enable the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.


We are an alpha-particle radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents.
Our new, proprietary class of theranostics enable the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Theranostics:
Understanding Which Patients Will Respond to Therapy
See the Tumor – Determine patient response, image tumor and identify tumor location
Treat the Tumor – Demonstrated to kill cancer cells with the ability to optimize patient dosing based on diagnostic images
Theranostics:
Understanding Which Patients Will Respond to Therapy

See the Tumor – Determine patient response, image tumor and identify tumor location

Treat the Tumor – Demonstrated to kill cancer cells with the ability to optimize patient dosing based on diagnostic images
Development Pipeline

Harnessing the Power of Alpha-Particles
Development Pipeline

Latest News:
Get Notified:
Let us keep you up to date on news and information
Contact Us:
Viewpoint Molecular
Targeting® , Inc.
2500 Crosspark Rd
Coralville, IA 52241
info@viewpointmt.com
(319) 665-2150
Investor Relations
JTC Team, LLC
Jenene Thomas
viewpoint@jtcir.com
(833) 475-8247
Latest News:
Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.
Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine
Get Notified:
Let us keep you up to date on news and information
Contact Us:
Viewpoint Molecular
Targeting, Inc.
2500 Crosspark Rd
Coralville, IA 52241
info@viewpointmt.com
(319) 665-2150
Investor Relations
JTC Team, LLC
Jenene Thomas
viewpoint@jtcir.com
(833) 475-8247